Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of MenACYW Conjugate Vaccine in Healthy Individuals (MET55)
NCT04143061Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2019
- Primary completion
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of meningococcal A conjugate vaccine in meningococcal disease (8 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants Who Achieved Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W at Day 30. Started Dec 2019; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT04143061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143061.